 |
|
Omission of Drug Dose Information—Reply
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In reply
We appreciate Hollenberg's interest in our article.1 As reported previously, participants were assigned to chlorthalidone (12.5-25 mg/d), amlodipine (2.5-10 mg/d), or lisinopril (10-40 mg/d). The distribution of doses prescribed at years 1, 3, and 5 are given in the Table. At year 1, the lowest dose was prescribed for 33.0%, 24.6% and 28.3% of the participants assigned to chlorthalidone, amlodipine, or lisinopril, respectively; the middle dose for 17.1%, 22.4%, and 15.2%; and the highest dose for 33.8%, 37.1%, and 34.3%. At year 5, the lowest dose was prescribed for 17.9%, 11.2%, and 14.0% of the participants, respectively; the middle dose for 12.9%, 13.9%, and 10.4%; and the highest dose for 40.8%, 47.6%, and 37.1%. Therefore, the majority of participants receiving lisinopril were receiving the higher dose levels of 20 mg or 40 mg during the course of the study. This pattern was consistent in participants with a . . . [Full Text of this Article]
AUTHOR INFORMATION
Mahboob Rahman, MD, MS;
Sara L. Pressel, MS;
Barry R. Davis, MD, PhD
RELATED ARTICLES
Omission of Drug Dose Information
Norman K. Hollenberg
Arch Intern Med. 2006;166(3):368.
EXTRACT
| FULL TEXT
Renal Outcomes in High-Risk Hypertensive Patients Treated With an Angiotensin-Converting Enzyme Inhibitor or a Calcium Channel Blocker vs a Diuretic: A Report From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
Mahboob Rahman, Sara Pressel, Barry R. Davis, Chuke Nwachuku, Jackson T. Wright, Jr, Paul K. Whelton, Joshua Barzilay, Vecihi Batuman, John H. Eckfeldt, Michael Farber, Mario Henriquez, Nelson Kopyt, Gail T. Louis, Mohammad Saklayen, Carol Stanford, Candace Walworth, Harry Ward, Thomas Wiegmann, and for the ALLHAT Collaborative Research Group
Arch Intern Med. 2005;165(8):936-946.
ABSTRACT
| FULL TEXT
|
